Firouzeh Ghaffari - Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute forReproductive Biomedicine, ACECR, Tehran, Iran
Azar Yahyaei - Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute forReproductive Biomedicine, ACECR, Tehran, Iran
Samira Vesali - Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

Background and Aim : Currently, optimal method of ovarian stimulation in patients with polycysticovarian syndrome is unknown. The present research aims to study the efficiency of minimal ovarianstimulation method in the treatment of infertile patients with polycystic ovarian syndrome and also theeffect of gonadotropin type on treatment cycles with antagonist GnRH.Methods : A total of 120 eligible patients were randomly allocated into four groups of ovarian stimulationto IVF/ ICSI: minimal ovarian stimulation with recombinant FSH, minimal ovarian stimulation with Humanmenopausal gonadotropin, mild ovarian stimulation with recombinant FSH and mild ovarian stimulationwith Human menopausal gonadotropin. IVF/ICSI outcomes were compared between groups. Data analysisincluded t test, ANOVA and χ2.Results : Demographic characteristics and hormonal profiles of the patients did not differ between groups.The statistical analysis showed that there were significant differences between groups regarding theprescribed dose of gonadotropin (p< 0.0001), stimulation duration (p< 0.0001), number of retrieved oocytes(p< 0.0001), number of obtained embryos (p< 0.0001), OHSS risk (p< 0.004) and also clinical pregnancyrate (p< 0.0001). There were no statistically significant differences in the fertilization rate (p< 0.289) andimplantation rate (p< 0.757), abortion rate (p< 0.199) and live birth (p< 0.896) between the groups.Conclusion : On the basis of present results the minimal ovarian stimulation with human menopausalgonadotropin is optimal method of control ovarian stimulation in patients with polycystic ovariansyndrome; however, larger randomized clinical trials are required.

polycystic ovarian syndrome, minimal ovarian stimulation, mild ovarian stimulation, Recombinant Follicle Stimulating Hormone, Urinary Human Menopausal Gonadotropin